Laser Therapy for Vulvovaginal Symptoms in Breast Cancer Patients

  • End date
    Oct 1, 2021
  • participants needed
  • sponsor
    Royal North Shore Hospital
Updated on 24 January 2021
Antonia Pearson, BMed FRACP
Primary Contact
Royal North Shore Hospital (4.8 mi away) Contact
+1 other location


To determine the efficacy of ablative carbon dioxide laser in the treatment of the signs and symptoms of vulvovaginal atrophy (VVA) or genitourinary syndrome of menopause (GSM) in women with breast cancer.


LAAVA 2 is a double blinded randomised placebo/sham-controlled trial assessing whether fractional ablative carbon dioxide is beneficial in improving symptoms in women with a history of early breast cancer. Patients will be randomly assigned in a 1:1 ratio to either active laser treatment or inactive "sham" laser treatment (setting of close to zero)

Participants will receive the 3 treatments approximately 4 weeks apart. Participants will then be followed up at twelve weeks post completion of treatment and twelve months post completion of treatment. At the twelve week follow up visit, after completion of study procedures, patients will be unblinded and those who received "sham" treatment will be allowed to crossover to "active" treatment if they wish.

Condition Vulvovaginal Atrophy, Genitourinary Symptoms and Ill-Defined Conditions, Genitourinary Symptoms and Ill-Defined Conditions, Genitourinary Symptoms and Ill-Defined Conditions
Treatment Placebo, CO2 Fractional Ablative Laser
Clinical Study IdentifierNCT03628092
SponsorRoyal North Shore Hospital
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Women with a history of early breast cancer >18 years of age
At baseline patients must have at least one of five symptoms rated at 5 on a 10cm VAS scale. Symptoms include vulvo-vaginal itch, dryness, burning, dysuria and dyspareunia
Three groups of patients will qualify
Treatment induced premature menopause 45 years of age (eg secondary to chemotherapy or oophorectomy) for >6 months
Premenopausal women on GNRH (gonadotrophin releasing hormone) agonist + tamoxifen or an aromatase inhibitor
Postmenopausal women on tamoxifen or an aromatase inhibitor
Willingness to give written informed consent and willingness to comply with the study
Up to date pap test / HPV (human papillomavirus) testing

Exclusion Criteria

Medical contraindication to the use of fractional ablative CO2 laser
Use of oestrogen therapies (systemic or local) in the 6 weeks prior to study treatment
Use of vaginal lubricants or moisturisers 14 days prior to the study treatment
Active or recent genitourinary infections (<30 days)
Genital prolapse (grade III)
Active or symptomatic vulvo-vaginal dermatological conditions (Lichen sclerosus, lichen planus, vulval psoriasis, Chron's disease, Hidradenitis Suppurativa, vulval dermatitis, candida, chronic vulvovaginal candidiasis, vulval intraepithelial neoplasia, genital warts)
Inability to tolerate the use of fractional ablative CO2 laser (eg vaginismus)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note